Adverse neonatal effects of maternal labetalol treatment

Crooks, Bruce; Deshpande, Suhas; Hall, Chris; Platt, Martin Ward; Milligan, David

doi:10.1136/fn.79.2.f150

Cited by 27 publications

(2 citation statements)

References 9 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…22 For example, labetalol treatment is associated with foetal growth restriction and neonatal bradycardia. 23 Angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists treatment lead to foetal loss in animals and cause neonatal anuric renal failure in human. 24 Searching for effective and safe reagent to treat PIH is still in urgent need.…”

Section: Discussionmentioning

confidence: 99%

Naringenin prevents pregnancy‐induced hypertension via suppression of JAK/STAT3 signalling pathway in mice

Duan

Geng

et al. 2021

Int J Clin Pract

View full text Add to dashboard Cite

Pregnancy-induced hypertension (PIH) is also called gestational hypertension, which is developed in the late pregnancy. It is estimated that 7%-10% of pregnancies are affected by PIH which compromises the normal pregnancy process. 1 PIH has been considered as the major cause of perinatal and maternal mortality. 2 The pathogenic mechanisms of PIH remain unclear. One of the major hallmarks in PIH is endothelial dysfunction. Endothelial cells line the internal lumen of the vasculature and participate in

show abstract

Section: Discussionmentioning

confidence: 99%

Naringenin prevents pregnancy‐induced hypertension via suppression of JAK/STAT3 signalling pathway in mice

Duan

Geng

et al. 2021

Int J Clin Pract

View full text Add to dashboard Cite

show abstract

“…Este deprime la conducción por medio del nodo auriculoventricular y, por consiguiente, permanecen contraindicados en pacientes con bradicardia severa o bloqueo auriculoventriculares (AV). Los pacientes que usan labetalol previamente o a lo largo de una intervención quirúrgica que involucre anestésicos en general tienen que ser vigilados minuciosamente debido a que sus efectos inotrópicos negativos tienen la posibilidad de ser aditivos con los de los anestésicos (Park, 1984;Crooks et al, 1998;Varon & Marik, 2008).…”

Section: Precauciones Y Contraindicacionesunclassified

Trastornos hipertensivos durante el embarazo

Paneque¹,

Fernández²,

Quiñones³

et al. 2022

View full text Add to dashboard Cite

La obra aborda aspectos importantes como: factores de riesgos, clasificación, algunas condiciones intrínsecas y extrínsecas vinculadas a esta patología, su etiopatogenia y fisiopatología, complicaciones maternas y perinatales; así como sus protocolos de atención, destacándose: el control de la hipertensión arterial, prevención de la convulsión eclámptica, vigilancia biológica y optimización de la extracción; con el propósito de estabilizar a la gestante en espera de la interrupción del embarazo como tratamiento definitivo que será dependiente de la edad gestacional y las condiciones clínicas materno fetales.

show abstract

Medications in Pregnancy and Lactation

Buhimschi¹,

Weiner²

2007

Management of High‐Risk Pregnancy

View full text Add to dashboard Cite

One of the least-developed areas of clinical pharmacology and drug research is the use of medication during pregnancy and lactation. This article is the first in a two-part series designed to familiarize physicians with many aspects of the drugs they commonly prescribe for pregnant and breast-feeding women. Almost every pregnant woman is exposed to some type of medication during pregnancy. Although the majority of pregnant and breast-feeding women consume clinically indicated or over-thecounter drug preparation regularly, only few medications have specifically been tested for safety and efficacy during pregnancy. There is scant information on the effect of common pregnancy complications on drug clearance and efficacy. Often, the safety of a drug for mothers, their fetuses, and nursing infants cannot be determined until it has been widely used. Absent this crucial information, many women are either refused medically important agents or experience potentially harmful delays in receiving drug treatment. Conversely, many drugs deemed "safe" are prescribed despite evidence of possible teratogenicity. Novel research and diagnostic applications evolving from the opportunities presented by the advances in genomics and proteomics are now beginning to affect clinical diagnosis, vaccine development, drug discovery, and unique therapies in a modern diagnostic-therapeutic framework-part of the new scientific field of theranostics. This review critically explores a number of recently raised issues in regard to the use of several classes of medications during gestation and seeks to provide a general and concise resource on drugs commonly used during pregnancy and lactation. It also seeks to make clinicians more aware of the controversies surrounding some drugs in an effort to encourage safer prescribing practices through consultation with a maternal-fetal medicine specialist and through references and Web sites that list up-to-date information.

show abstract

Adverse neonatal effects of maternal labetalol treatment

Cited by 27 publications

References 9 publications

Naringenin prevents pregnancy‐induced hypertension via suppression of JAK/STAT3 signalling pathway in mice

Naringenin prevents pregnancy‐induced hypertension via suppression of JAK/STAT3 signalling pathway in mice

Trastornos hipertensivos durante el embarazo

Medications in Pregnancy and Lactation

Contact Info

Product

Resources

About